We are live on ! Find out more
VVM

Versant Venture Management Portfolio holdings

AUM $141M
1-Year Est. Return 190.82%
This Fund
S&P 500
This Quarter Est. Return
+10.28%
1 Year Est. Return
+190.82%
3 Year Est. Return
+375.7%
5 Year Est. Return
+81.85%
10 Year Est. Return
+4,735.29%
AUM
$103M
AUM Growth
-$286M
Cap. Flow
-$289M
Cap. Flow %
-280.49%
Top 10 Hldgs %
100%
Holding
8
New
1
Increased
–
Reduced
1
Closed
1

Top Buys

No buys this quarter

Top Sells

Rank Stock Value
1
RYZB
RayzeBio, Inc. Common Stock
RYZB
+$321M
2
ADVM
Adverum Biotechnologies
ADVM
+$15

Sector Composition

Rank Sector Weight
1 Healthcare 69.55%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CRSP icon
1
CRISPR Therapeutics
CRSP
$4.68B
$34M 32.95%
498,558
– –
RPTX
2
DELISTED
Repare Therapeutics
RPTX
$12.5M 12.09%
2,646,657
– –
GRTS
3
DELISTED
Gritstone bio, Inc. Common Stock
GRTS
$9.15M 8.87%
3,561,150
– –
ADVM
4
DELISTED
Adverum Biotechnologies
ADVM
$7.17M 6.95%
506,822
-1
-0% -$15
PASG icon
5
Passage Bio
PASG
$14.7M
$6.7M 6.49%
247,988
– –
ALGS icon
6
Aligos Therapeutics
ALGS
$26.3M
$2.27M 2.2%
92,815
– –
RYZB
7
DELISTED
RayzeBio, Inc. Common Stock
RYZB
– –
-5,158,161
Closed -$321M

Similar funds

POIA
Pin Oak Investment Advisors Houston, Texas $141M AUM 20.83% 1-Year Est. Return
MAM
Maytree Asset Management Hong Kong $141M AUM 114% 1-Year Est. Return
TM
TFJ Management Somerville, Massachusetts $141M AUM 9.28% 1-Year Est. Return
IA
IF Advisors San Antonio, Texas $141M AUM
KCM
Kalehua Capital Management Dallas, Texas $141M AUM
RB
Renasant Bank Tupelo, Mississippi $141M AUM 16.9% 1-Year Est. Return
YEPX
Yorktown Energy Partners XI New York $142M AUM 130.51% 1-Year Est. Return
CFGW
Chancellor Financial Group WB Wilkes-Barre, Pennsylvania $141M AUM 23.22% 1-Year Est. Return

Versant Venture Management's Q1 2024 Portfolio in Review

As of Q1 2024, Versant Venture Management held 8 positions worth $103M, down 73% from $389M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Versant Venture Management withdrew a net $289M in Q1 2024, closing 1 position and reducing 1 holding. Its most notable exit was RayzeBio, Inc. Common Stock, an estimated $321M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 70% of assets, down from 100% a quarter earlier.

  • Versant Venture Management's biggest Q1 2024 reduction was Adverum Biotechnologies, cutting an estimated $15.
  • Versant Venture Management fully exited RayzeBio, Inc. Common Stock in Q1 2024, selling an estimated $321M.
  • Versant Venture Management's ten largest holdings make up 100% of its $103M portfolio in Q1 2024.
  • Versant Venture Management opened 1 new position and closed 1 in Q1 2024.
  • Versant Venture Management's portfolio value fell 73% quarter-over-quarter to $103M.

Based on Versant Venture Management's 13F filing for Q1 2024, filed 3 May 2024.